drugset / Trial / NCT00195585

Study Evaluating Isovorin in Colon Cancer

NCT00195585

Phase 3 Completed 650 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.

Timeline

Start
2002-10
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levoleucovorin Unknown
Subject UFT Unknown

Indications